Filtered By:
Drug: Vytorin
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 235 results found since Jan 2013.
Understanding the molecular mechanisms of statin pleiotropic effects
Arch Toxicol. 2023 Apr 21. doi: 10.1007/s00204-023-03492-6. Online ahead of print.ABSTRACTStatins represent the cornerstone of pharmacotherapy for the prevention of atherosclerotic cardiovascular disease. These medications not only reduce low-density lipoprotein cholesterol (LDL-C) via inhibition of 3-hydroxy-3-methylglutarate attached to CoA reductase, the key rate-limiting step in the cholesterol biosynthetic pathway, but also upregulate expression of the low-density lipoprotein receptor, improving serum clearance. Given LDL-C is a causal risk factor for the development of atherosclerosis, these complementary mechanisms ...
Source: Archives of Toxicology - April 21, 2023 Category: Toxicology Authors: Charles A German James K Liao Source Type: research
Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction
ConclusionImplementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events.
Source: Cardiovascular Drugs and Therapy - April 13, 2023 Category: Cardiology Source Type: research
Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis
CONCLUSIONS: Moderate-intensity statin with ezetimibe combination therapy showed similar cardiovascular benefits to those of high-intensity statin monotherapy with lower intolerance-related drug discontinuation or dose reduction in elderly patients with ASCVD having a higher risk of intolerance, nonadherence, and discontinuation with high-intensity statin therapy. (RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases [RACING Trial]; NCT03044665).PMID:37019580 | DOI:10.1016/j.jacc.2023.02.007
Source: Atherosclerosis - April 5, 2023 Category: Cardiology Authors: Sang-Hyup Lee Yong-Joon Lee Jung Ho Heo Seung-Ho Hur Hyun Hee Choi Kyung-Jin Kim Ju Han Kim Keun-Ho Park Jung Hee Lee Yu Jeong Choi Seung-Jun Lee Sung-Jin Hong Chul-Min Ahn Byeong-Keuk Kim Young-Guk Ko Donghoon Choi Myeong-Ki Hong Yangsoo Jang Jung-Sun Ki Source Type: research
Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial
AbstractPurpose of ReviewThe Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) demonstrated the clinical benefit of the combination of ezetimibe-simvastatin compared to placebo-simvastatin following acute coronary syndrome (ACS). This review highlights key findings from this study with particular attention to the practice-changing impact on guidelines for low-density lipoprotein cholesterol (LDL-C) reduction after ACS, especially among high-risk populations.Recent FindingsConsistent reductions in LDL-C have been reported with newer lipid-lowering therapies (proprotein convertase subtilisin/k...
Source: Current Atherosclerosis Reports - February 10, 2023 Category: Cardiology Source Type: research
World Heart Federation Cholesterol Roadmap 2022
CONCLUSIONS: The adverse effects of LDL-cholesterol and apo B containing lipoprotein exposure are cumulative and result in ASCVD. These are preventable by implementation of different strategies, aimed at efficiently tackling atherosclerosis at different stages throughout the human life-course. Preventive strategies should therefore be updated to implement health policy, lifestyle changes and when needed pharmacotherapies earlier with investment in, and a shift in focus towards, early preventive strategies that preserve cardiovascular health rather than treat the consequences of ASCVD.PMID:36382159 | PMC:PMC9562775 | DOI:10.5334/gh.1154
Source: Atherosclerosis - November 16, 2022 Category: Cardiology Authors: Kausik K Ray Brian A Ference Tania S éverin Dirk Blom Stephen J Nicholls Mariko H Shiba Wael Almahmeed Rodrigo Alonso Magdalena Daccord Marat Ezhov Rosa Fern ández Olmo Piotr Jankowski Fernando Lanas Roopa Mehta Raman Puri Nathan D Wong David Wood Dong Source Type: research
Yield of Dual Therapy With Statin and Ezetimibe in the Treat Stroke to Target Trial
CONCLUSIONS: In the TST trial (Treat Stroke to Target), targeting an LDL cholesterol of < 70 mg/dL with a combination of statin and ezetimibe compared with 100±10 mg/dL consistently reduced the risk of subsequent stroke.REGISTRATION: URL: https://www.CLINICALTRIALS: gov; Unique identifier: NCT01252875. URL: clinicaltrialsregister.eu; Unique identifier: EUDRACT2009-A01280-57.PMID:36154103 | DOI:10.1161/STROKEAHA.122.039728
Source: Atherosclerosis - September 26, 2022 Category: Cardiology Authors: Pierre Amarenco Jong S Kim Julien Labreuche Hugo Charles Maurice Giroud Byung-Chul Lee Philippa C Lavall ée Marie-H élène Mahagne Elena Meseguer Norbert Nighoghossian Philippe Gabriel Steg Éric Vicaut Eric Bruckert Treat Stroke to Target Investigators Source Type: research
Projected Impact of Treatment Intensification with Satin, Ezetimibe, and Statin plus Ezetimibe Fixed-Dose Combination on MACE Across Six Countries
CONCLUSION: The 2019 ESC/EAS guideline-based treatment intensification with strategies based on statin, ezetimibe, and statin plus ezetimibe FDC is estimated to result in a substantial population-level benefit in terms of MACE averted compared to BAU.PMID:36134461 | DOI:10.1093/eurjpc/zwac214
Source: Atherosclerosis - September 22, 2022 Category: Cardiology Authors: Michel Farnier Raul D Santos Juan Cosin-Sales Marat V Ezhov Jian Liu Denis Granados Serena Santoni Irfan Khan Alberico L Catapano Source Type: research
Lipid Lowering Therapy: An Era Beyond Statins
Curr Probl Cardiol. 2022 Jul 30:101342. doi: 10.1016/j.cpcardiol.2022.101342. Online ahead of print.ABSTRACTDyslipidemia, specifically elevated LDL cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke. Statins, a class of drugs that exert their effects by inhibiting HMG-CoA reductase, a key enzyme in the synthesis of cholesterol, have been the mainstay of therapy for the primary prevention of cardiovascular disease and lipids reduction. Statins are associated with side effects, most commonly myopathy and myalgias, despite their proven efficacy....
Source: Atherosclerosis - August 2, 2022 Category: Cardiology Authors: Toufik Abdul-Rahman Syed Muhammad Awais Bukhari Emiliano Cantu Herrera Wireko Andrew Awuah Jannel Lawrence Heloisa de Andrade Neal Patel Rohan Shah Raheel Shaikh Camilo Andr és Avendaño Capriles Sebahat Ulusan Shahzaib Ahmad Anna Corriero Adriana C Mare Source Type: research
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
The new BMJ Rapid Recommendations addressed the following question: should we add another lipid-lowering drug in adults with low-density lipoprotein-cholesterol (LDL-C) over 1.8 mmol/L using a maximal dose of statins or intolerant to statins?1 Why is this question important? Both proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and ezetimibe have been shown to reduce LDL-C by approximately 60% and approximately 20%, respectively, and correspondingly may reduce major adverse cardiovascular events (MACE), including all-cause death, cardiovascular death, myocardial infarction (MI) and stroke. However, the bene...
Source: Heart - July 27, 2022 Category: Cardiology Authors: White, H. D. Tags: Editorials Source Type: research
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome
This study was a prospective, randomized controlled study. A total of 136 patients with extremely high-risk ACS with LDL-C ≥ 3.0 mmol/L after percutaneous coronary intervention (PCI) treatment were randomly assigned 1:1 to the control group (atorvastatin 40 mg/day and ezetimibe 10 mg/day) or the evolocumab group (evolocumab 140 mg every 2 weeks combined with atorvastatin 40 mg/day and ezetimibe 10 mg/day). We compared the blood lipid profiles, major adverse cardiovascular events (MACEs), and adverse reactions. MACEs included cardiogenic death, nonfatal myocardial infarction, nonfatal stroke, and readmission due to angina...
Source: International Heart Journal - July 13, 2022 Category: Cardiology Authors: Yan Hao Yu-Lin Yang Yong-Chao Wang Jian Li Source Type: research
